{"organizations": [], "uuid": "4045e730b2ec04b9aaf16fc7930826cee79b066d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-tg-therapeutics-jiangsu-hengrui-an/brief-tg-therapeutics-jiangsu-hengrui-announce-agreement-for-btk-inhibitor-program-for-treatment-of-hematologic-malignancies-idUSFWN1P30KD", "country": "US", "domain_rank": 408, "title": "BRIEF-TG Therapeutics, Jiangsu Hengrui Announce Agreement For BTK Inhibitor Program For Treatment Of Hematologic Malignancies", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-08T14:43:00.000+02:00", "replies_count": 0, "uuid": "4045e730b2ec04b9aaf16fc7930826cee79b066d"}, "author": "", "url": "https://www.reuters.com/article/brief-tg-therapeutics-jiangsu-hengrui-an/brief-tg-therapeutics-jiangsu-hengrui-announce-agreement-for-btk-inhibitor-program-for-treatment-of-hematologic-malignancies-idUSFWN1P30KD", "ord_in_thread": 0, "title": "BRIEF-TG Therapeutics, Jiangsu Hengrui Announce Agreement For BTK Inhibitor Program For Treatment Of Hematologic Malignancies", "locations": [], "entities": {"persons": [{"name": "hengrui", "sentiment": "none"}], "locations": [{"name": "jiangsu hengrui", "sentiment": "none"}], "organizations": [{"name": "brief-tg therapeutics", "sentiment": "negative"}, {"name": "treatment of hematologic malignancies reuters", "sentiment": "none"}, {"name": "reuters) - jiangsu hengrui medicine co ltd", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 45 PM / Updated 9 minutes ago BRIEF-TG Therapeutics, Jiangsu Hengrui Announce Agreement For BTK Inhibitor Program For Treatment Of Hematologic Malignancies Reuters Staff 1 Min Read \nJan 8 (Reuters) - Jiangsu Hengrui Medicine Co Ltd : \n* TG THERAPEUTICS AND JIANGSU HENGRUI MEDICINE ANNOUNCE GLOBAL LICENSE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF NOVEL BTK INHIBITOR PROGRAM FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES \n* TG THERAPEUTICS INC - ‍ UNDER TERMS, HENGRUI WILL RECEIVE AN UP-FRONT LICENSING FEE AND NEAR-TERM MILESTONES, PAYABLE IN TG COMMON STOCK​ \n* TG THERAPEUTICS INC - ‍HENGRUI IS ELIGIBLE TO RECEIVE COLLABORATION AND LICENSING PAYMENTS OF ABOUT $350 MILLION, IN ADDITION TO ROYALTIES ON FUTURE SALES​  ", "external_links": [], "published": "2018-01-08T14:43:00.000+02:00", "crawled": "2018-01-08T15:00:42.001+02:00", "highlightTitle": ""}